AstraZeneca PLC closed 22.92% short of its 52-week high of £133.88, which the company reached on September 3rd.

The AstraZeneca PLC ADR AZN slid 2.83% to $64.87 Thursday, on what proved to be an all-around poor trading session for the ...

Learn more about whether AstraZeneca PLC or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Results of Annual General Meeting held on 11 April 2025 AstraZeneca PLC announced the results of the voting at its Annual General Meeting (AGM) today. As proposed in the Notice of AGM, all ...

AstraZeneca PLC has a one year low of $62.75 and a one year high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.93 and a quick ratio of 0.74.

In its fourth quarter 2024 investor letter, Parnassus Growth Equity Fund emphasized stocks such as AstraZeneca PLC (NASDAQ:AZN). AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that ...

AstraZeneca's (LON:AZN) stock up by 7.5% over the past three months. Since the market usually pay for a company’s long-term financial health, we decided to study the company’s fundamentals to see if ...

Reserve your spot now. On Monday, AstraZeneca Plc AZN released high-level results from the CALYPSO Phase 3 trial designed to evaluate the efficacy and safety of eneboparatide in adults with ...

AstraZeneca Plc’s experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful ...

Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £153.18. The ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of £110.00. The company’s shares opened today at p10,500. ...